title: Talaporfin sodium.
abstract: BACKGROUND
  Despite therapeutic advances, cancer remains the cause of an estimated 23% of deaths in the USA. New treatments for malignancy are greatly needed.
  
  
  METHODS
  Talaporfin sodium is a light-activated drug that causes tissue death through induction of apoptosis. Systemic antitumor effects mediated by CD8(+) T cells have been demonstrated in preclinical studies, providing a mechanism for distant response of tumors noted in clinical trials. Talaporfin sodium is approved in Japan for early-stage endobronchial cancer. Phase I and II studies in solid tumors have shown tumor regression in patients refractory to other therapies. Phase III pivotal studies against hepatocellular carcinoma as monotherapy and liver-metastatic colorectal cancer in combination with chemotherapy are ongoing. Talaporfin sodium is also in studies in men with symptomatic benign prostatic hyperplasia. Substantial safety data from clinical trials so far indicate that the drug is well tolerated.
  
  
  RESULTS
  Talaporfin sodium has a broad safety profile and a mode of action that could affect growth in treated and untreated tumors.
  
  
  CONCLUSIONS
  Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.
authors.affiliation: Light Sciences Oncology, 15405 SE 37th Street, Suite 100, Bellevue, WA 98006, USA. syshiw@lsoncology.com
authors.forename: S
authors.initials: S
authors.lastname: Wang
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Bromley
authors.forename: Leon
authors.initials: L
authors.lastname: Xu
authors.forename: James C
authors.initials: JC
authors.lastname: Chen
authors.forename: Llew
authors.initials: L
authors.lastname: Keltner
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D009367:Neoplasm Staging; D009369:Neoplasms; D010087:Oxides / Q000378:metabolism; D011166:Porphyrins / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D010087:Oxides; D011166:Porphyrins; C053434:Talaporfin